Computational antibody design
Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.
Monica Berrondo, CEO
Monica Berrondo, Ph.D., is an entrepreneur, scientist, and software engineer. Her expertise lies in antibody structure-prediction and analysis, protein functional analysis, protein mutational analysis, and computational approaches to complex scientific problems.
Susana Kaufmann, CTO
Macromoltek is hiring for these roles
|Machine Learning Engineer||Austin, TX / Remote|